The number of endoscopes sold is significantly higher than what the market had predicted in Ambu's second quarter. However, this has not brought about the kind of revenue that analysts had expected. The full-year outlook is maintained.
Ambu is intensifying its efforts to create the next generation of its duodenoscopes. A number of competitors are circling, and an upcoming tender is a good opportunity for income. CEO Juan Jose Gonzalez calls the new duodenoscope the biggest earner of the future.
Following an approval from the US FDA in 2018, technology firm Bose is now launching its new low-cost, self-tuning hearing aid which works in the same way as the upcoming OTC devices in the US.
US electronics company Bose's announced launch of a new, cheap self-tuning hearing aid won't cause sales to plummet for established hearing aid manufacturers, analysts believe. Demant welcomes the competition and WSA plans to test Bose's new solution to understanding its technology.
Ambu expects to launch Vivasight 2 on the US market during Q3 of its financial year 2020/2021
While Northera sales plummeted more rapidly than expected, Lundbeck plans for its other products to make up for this loss, especially now that the migraine drug Vyepti is gaining momentum.
Sales of the drug Northera, which is no longer protected by patents, plummeted in Lundbeck's first quarter, while most other key products surpassed analysts' forecasts. This means the firm brought in more revenue than the market expected.
The tables have turned at GN Store Nord as the headset division GN Audio has now surpassed the GN Hearing business leg for several quarters. The chief of the latter, Gitte Aabo, is hardly concerned by this development as she sees it as an advantage to have a successful sister under the same parent company.
When Ambu reveals its Q2 financial report on Wednesday morning, Sydbank analyst Søren Løntoft Hansen expects to see continued strong growth for single-use endoscopes.
An unnamed source reveals that the new lawsuit revolves around the financial part of the agreement and might enable fines.
The first quarter was a good one for Almirall, and the new CEO hopes to live up to the 2021 guidance with the help of two potential EU approvals.
Medtech company Coloplast has set aside a further USD 33m to pay for compensation in the remaning cases over its vaginal mesh product in the US. The covid-19 crisis has delayed court cases and increased the cost of legal counsel, but the financial director expects this amount to be enough to but the cases behind them.
In an EUR 200m deal, hearing aid company Sonova has acquired audio firm Sennheiser's Consumer Division in order to better position itself in the new 'hearables market'. The Swiss company also aims to prepare for a future sales channel for low-cost hearing aids in the US, according to analyst.
The lockdowns caused by the covid-19 pandemic will still affect Lundbeck's second quarter, and the company will also be affected by expiring patents, says Sydbank analyst Søren Løntoft Hansen.
Waiving patents may be a solution in the long term but does not generate more vaccines now, say EU countries.
As drug samples couldn't be cooled down due to the lack of power during the storms in Texas in February, Novo Nordisk is voluntarily recalling nearly 1,500 insulin products.
Japanese medtech firm Olympus adds new goal for carbon neutrality and circular economy to the firm's ESG policy.
After working under the radar for decades, privately-owned WS Audiology is now entering a more transparent playing field to gain better footing in the battle for the smartest brains and for partner and investor interest. Analysts view this new strategy as preparation for taking the company public.
The trial between collaborative partners Genmab and Janssen is moving along, but according to Jan van de Winkel it's too early to conclude when a verdict will be made.
Christophe Bourdon, Orphazyme's new CEO, is candid about the group's main candidate against ALS, arimoclomol, came out of its phase-3 trial with weak results.
Olivier Bohuon, the chair of Leo Pharma's board of directors, is resigning from his position due to personal reasons. The search for his replacement is now underway.
Spain has backed a US proposal to waive intellectual property rights for coronavirus vaccines, breaking ranks with Germany and complicating efforts by the European Union to form a common stance.
The US government purchases the last part of its option for Bavarian Nordic smallpox vaccines at USD 12m.
Miss anything?
Genmab keeps expanding its workforce in Europe, the US and Japan to prepare for handling drug commercialization on its own.
Associate Director, QA GCP/PV - Genmab 
Global Market Access Manager - ALK Director, Head of Trial Management - Genmab 
Senior Scientist in Antibody Engineering - Lundbeck 
Cross Functional CMC/Safety Toxicologist, Ascendis Pharma Pharmacovigilance Auditor - ALK 
Associate Medical Director, Translational Medicine - Y-mAbs Therapeutics 
Pharmacovigilance Compliance Specialist with expertise in regulatory surveillance Senior/Principal PV Associate - Lundbeck Principal Biostatistician - ALK Senior Programming Manager - Genmab Immunotoxicologist - Lundbeck 
Experienced Content Manager, life science - UNEEG medical 
(Senior) Regulatory Science Specialist - IWA Consulting Senior CMC Specialist, Analytical - Genmab Scientific Data Engineer - Novo Nordisk Senior Scientist (Toxicology) / Nonclinical Safety Specialist Principal Scientist/Scientific Director, protein drug discovery and development - Y-mAbs Therapeutics Senior Programming Manager, Clinical Data Standards - Genmab QA Professional with a broad interest in quality Analysis Chemist for QC Analytics - ALK Manager, QA GMP - Genmab 
Senior Manager – Corporate Development and M&A, Orifarm 
Manager, SOX Compliance - Zealand Pharma Department Manager - Consumer Healthcare, Orifarm 
